SCHEMBL19465

SCHEMBL19465

COc1ncccc1CBr

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 2/20 0.46
HTR2C P28335 2/20 0.46
KDM1A O60341 5/20 0.46
MAOA P21397 2/20 0.46
SLC13A5 Q86YT5 1/20 0.46
MAOB P27338 1/20 0.46
APLNR P35414 1/20 0.43
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
HTR2B P41595 1/20 0.40
BTK Q06187 1/20 0.39
CHRNB4 P30926 2/20 0.38
CHRNA3 P32297 2/20 0.38
CYP3A4 P08684 2/20 0.36
CYP2C19 P33261 1/20 0.36
CYP2C9 P11712 1/20 0.36
PDE1A P54750 1/20 0.36
PDE1B Q01064 1/20 0.36
PDE1C Q14123 1/20 0.36
GRM5 P41594 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21847112 0.82 SLC13A5 (0.47) SLC13A5MEN1KMT2APDE1APDE1B
SCHEMBL91503 0.82 SLC13A5 (0.50) HTR2AHTR2CKDM1AMAOASLC13A5
SCHEMBL14983860 0.81 KDM1A (0.43) HTR2AHTR2CKDM1AMAOASLC13A5
SCHEMBL18440 0.80 MEN1 (0.60) HTR2AHTR2CKDM1AMAOASLC13A5
SCHEMBL2960548 0.80 SLC13A5 (0.49) HTR2AHTR2CKDM1AMAOASLC13A5
SCHEMBL18291875 0.80 SLC13A5 (0.49) HTR2AHTR2CKDM1AMAOASLC13A5
SCHEMBL6588356 0.80 SLC13A5 (0.49) HTR2AHTR2CKDM1AMAOASLC13A5
SCHEMBL31365171 0.80 MEN1 (0.60) HTR2AHTR2CKDM1AMAOASLC13A5
SCHEMBL129593 0.80 KDM1A (0.46) HTR2AHTR2CKDM1AMAOASLC13A5
SCHEMBL29587038 0.80 KDM1A (0.46) HTR2AHTR2CKDM1AMAOASLC13A5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117024411-B Isoquinoline as HPK1 inhibitor 豪夫迈·罗氏有限公司 2026-05-19 CN disclosed
EP-4608810-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF USE TO TREAT HYPOPARATHYROIDISM AND OSTEOPOROSIS Septerna, Inc. (US) 2025-09-03 EP disclosed
EP-4219463-B1 TERPYRIDINE DIKETONE COMPOUND OR SALT THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF SHENZHEN SALUBRIS PHARM CO LTD (CN) 2025-01-15 EP disclosed
US-20240360082-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2024-10-31 US disclosed
EP-4373809-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS Novartis AG (CH) 2024-05-29 EP disclosed
US-20240166627-A1 Terpyridinedione compound or salt thereof, and preparation method and application thereof SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (CN) 2024-05-23 US disclosed
CN-110914280-B 6H-thieno [2,3-e ] [1,2,4] triazolo [3,4-c ] [1,2,4] triazab derivatives 阿尤米制药公司 2024-05-03 CN disclosed
CN-117980292-A Substituted pyridone compounds for the treatment of orthomyxoviral infections 诺华股份有限公司 2024-05-03 CN disclosed
WO-2024091498-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF USE TO TREAT HYPOPARATHYROIDISM AND OSTEOPOROSIS SEPTERNA, INC. (US) 2024-05-02 WO disclosed
CN-116648244-B Terpyridyl dione compound or salt thereof, and preparation method and application thereof 深圳信立泰药业股份有限公司 2023-12-15 CN disclosed
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-09-06 US disclosed
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-09-06 US disclosed
WO-2012027261-A1 SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-03-01 WO disclosed
WO-2012027261-A1 SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-03-01 WO disclosed
WO-2011115804-A1 SGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2011-09-22 WO disclosed
US-20090042726-A1 Novel Herbicides SYNGENTA LIMITED (GB) 2009-02-12 US disclosed
US-20090042726-A1 Novel Herbicides SYNGENTA LIMITED (GB) 2009-02-12 US disclosed
US-20090042726-A1 Novel Herbicides SYNGENTA LIMITED (GB) 2009-02-12 US disclosed
EP-1965644-A1 NOVEL HERBICIDES Syngenta Limited (GB) 2008-09-10 EP disclosed
WO-2007071900-A1 NOVEL HERBICIDES SYNGENTA LIMITED (GB) 2007-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240166627-A1 Terpyridinedione compound or salt thereof, and preparation method and application thereof TNF, MAPKAPK2, MAPK1 HTR2A 4137/4885HTR2C 3893/4885KDM1A 2781/4885
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES GCKR, GCK, SLC5A2 HTR2A 3775/4885HTR2C 3581/4885KDM1A 3980/4885
US-20090042726-A1 Novel Herbicides DDT, CBR3, CBR1 HTR2A 2074/4885HTR2C 1817/4885KDM1A 446/4885
US-20240360082-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS PNPO, PDXK, PLPBP HTR2A 3264/4885HTR2C 2441/4885KDM1A 1362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.